…
CannaPharmaRX, Inc. engages in acquisition, development, and operation of cannabis cultivation facilities in Germany, Israel, Portugal, and Canada. It produces and sells dried cannabis flower and trim shake, as well as unique genetics, medical cannabis, and craft products. The company is based in Cremona, Canada.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
CannaPharmaRx, Inc. (CPMD) is a microcap issuer quoted on the OTC Pink market that identifies itself in public filings as operating in the cannabis/cannabinoid sector, but public disclosures are limited. Long-term growth could be supported by broader legalization trends, expanding consumer acceptance and successful execution on product or distribution initiatives, and the company may benefit if management improves operational transparency.
The primary risk is limited and intermittent public disclosure, thin trading liquidity and substantial regulatory and operational uncertainty in the cannabis sector, which could impair investor visibility and value realization.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -11.13M | -9.91M | 3.69M | -8.53M | -8.83M |
| Net income | -11.13M | -9.91M | 3.69M | -8.53M | -10.34M |
| Selling general administrative | 0.96M | 0.59M | 1.25M | 4.91M | 2.61M |
| Selling and marketing expenses | - | 0.00M | 0.10M | - | - |
| Gross profit | -2.08M | -2.94M | -0.07M | - | -0.01M |
| Reconciled depreciation | - | 0.00M | 0.30M | 0.29M | 0.00M |
| Ebit | - | -7.64M | -1.57M | -5.21M | -2.99M |
| Ebitda | -8.68M | -7.64M | -1.45M | -5.95M | -2.61M |
| Depreciation and amortization | - | 0.00M | 0.13M | - | 0.38M |
| Operating income | -3.35M | -3.61M | -1.58M | -5.21M | -2.99M |
| Other operating expenses | 4.71M | 4.43M | 1.58M | - | 2.62M |
| Interest expense | 2.45M | 2.26M | 1.70M | 2.29M | 1.51M |
| Tax provision | - | - | - | 0.00M | 0.00M |
| Net interest income | -2.45M | -2.26M | -2.02M | -2.29M | -1.51M |
| Income tax expense | - | - | 2.69M | - | 1.51M |
| Total revenue | 1.36M | 0.82M | 0.00M | 0.00M | 0.00M |
| Total operating expenses | 1.26M | 0.67M | 1.58M | 5.21M | 2.62M |
| Cost of revenue | 3.45M | 3.75M | 0.07M | - | 0.01M |
| Total other income expense net | -7.78M | -6.30M | 5.27M | -1.03M | -5.84M |
| Net income from continuing ops | -11.13M | -9.91M | -7.50M | -8.53M | -8.83M |
| Net income applicable to common shares | - | - | - | -8.53M | -8.83M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 7.02M | 10.84M | 11.75M | 5.41M | 0.11M |
| Other current assets | 0.03M | 0.02M | 0.07M | 0.01M | 0.00M |
| Total liab | 37.17M | 30.65M | 23.90M | 22.76M | 13.04M |
| Total stockholder equity | -30.15M | -19.81M | -12.15M | -17.34M | -12.93M |
| Other current liab | 10.79M | 12.53M | 5.37M | 1.20M | 0.51M |
| Common stock | 0.07M | 0.07M | 0.04M | 0.03M | 0.01M |
| Capital stock | 0.70M | 0.70M | 3.33M | 2.59M | 0.55M |
| Retained earnings | -112.32M | -101.18M | -91.28M | -94.70M | -86.16M |
| Other liab | - | - | - | - | -0.00M |
| Other assets | - | - | 0.00M | - | - |
| Cash | 0.00M | 0.00M | 0.00M | 0.00M | 0.03M |
| Total current liabilities | 31.59M | 25.75M | 18.16M | 17.17M | 13.04M |
| Current deferred revenue | 0.26M | - | 0.34M | - | 0.38M |
| Net debt | 20.65M | 14.06M | 12.93M | 8.93M | 8.99M |
| Short term debt | 15.07M | 8.44M | 7.20M | - | 9.02M |
| Short long term debt | 14.07M | 8.44M | 7.01M | 8.93M | 9.02M |
| Short long term debt total | 20.65M | 14.06M | 12.94M | - | 9.02M |
| Other stockholder equity | 81.52M | 80.68M | 75.83M | 0.24M | 73.06M |
| Property plant equipment | - | - | - | 5.24M | 0.01M |
| Total current assets | 1.31M | 1.02M | 1.20M | 0.10M | 0.03M |
| Long term investments | 0.00M | 4.52M | 4.52M | 0.08M | 0.08M |
| Net tangible assets | - | - | - | -19.90M | -13.47M |
| Net receivables | 0.16M | 0.02M | 0.06M | 0.02M | 0.00M |
| Long term debt | 0.55M | - | - | - | - |
| Inventory | 1.12M | 1.00M | 1.13M | - | -0.00M |
| Accounts payable | 5.47M | 4.78M | 5.59M | 6.88M | 3.13M |
| Accumulated other comprehensive income | -0.06M | 0.56M | -0.04M | - | -0.37M |
| Non currrent assets other | 5.71M | 5.30M | -0.00M | - | 0.01M |
| Non current assets total | 5.71M | 9.82M | 10.55M | 5.31M | 0.08M |
| Capital lease obligations | 6.03M | 5.62M | 5.93M | 5.59M | - |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | - | 0.00M | -0.09M | -0.12M | 0.49M |
| Change to liabilities | - | - | - | 1.42M | -0.45M |
| Total cashflows from investing activities | -0.01M | - | -0.08M | -0.12M | 0.53M |
| Net borrowings | 0.79M | 1.70M | 2.35M | 0.97M | 0.51M |
| Total cash from financing activities | 0.79M | 1.70M | 2.35M | 1.40M | 1.34M |
| Change to operating activities | - | - | - | 2.53M | 0.03M |
| Net income | -11.13M | -9.91M | 3.69M | -8.53M | -8.83M |
| Change in cash | -0.00M | 0.00M | -0.00M | -0.03M | -0.31M |
| Begin period cash flow | 0.00M | 0.00M | 0.00M | 0.03M | 0.33M |
| End period cash flow | 0.00M | 0.00M | 0.00M | 0.00M | 0.03M |
| Total cash from operating activities | -0.79M | -1.70M | -2.27M | -1.45M | -2.41M |
| Issuance of capital stock | - | - | -0.06M | 0.44M | 0.83M |
| Depreciation | - | 0.00M | 0.13M | 0.29M | 0.00M |
| Other cashflows from investing activities | -0.01M | - | - | - | - |
| Change to inventory | -1.99M | -0.51M | -1.13M | - | - |
| Change to account receivables | -1.02M | -0.00M | -0.04M | - | - |
| Other cashflows from financing activities | 0.79M | 1.70M | 2.35M | - | 1.36M |
| Change to netincome | - | - | - | 2.36M | 5.58M |
| Capital expenditures | 0.01M | 0.00M | 0.08M | 0.12M | 0.01M |
| Change in working capital | 0.43M | 0.02M | -0.82M | 3.95M | -0.42M |
| Stock based compensation | 0.14M | 0.00M | 0.18M | 0.18M | 0.36M |
| Other non cash items | 9.91M | 8.18M | -5.27M | 1.23M | 1.52M |
| Free cash flow | -0.79M | -1.70M | -2.36M | -1.56M | -2.42M |
Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| CPMD CannaPharmaRx Inc |
- -% |
0.00 | - | - | 0.83 | 11.05 | 13.35 | 6.69 |
| MKKGY Merck KGaA ADR |
-0.68 2.09% |
31.83 | 21.25 | 14.93 | 3.10 | 2.14 | 3.60 | 12.98 |
| MKGAF MERCK Kommanditgesellschaft auf Aktien |
- -% |
163.45 | 24.86 | 15.11 | 3.13 | 1.98 | 3.08 | 18.89 |
| TAK Takeda Pharmaceutical Co Ltd ADR |
0.38 1.77% |
21.79 | - | 10.96 | 0.01 | 1.20 | 2.94 | 23.11 |
| TKPHF Takeda Pharmaceutical Co. Ltd. |
- -% |
43.05 | - | 10.66 | 0.01 | 1.16 | 2.94 | 23.11 |
CannaPharmaRX, Inc. engages in acquisition, development, and operation of cannabis cultivation facilities in Germany, Israel, Portugal, and Canada. It produces and sells dried cannabis flower and trim shake, as well as unique genetics, medical cannabis, and craft products. The company is based in Cremona, Canada.
| Name | Title | Year Born |
|---|---|---|
| Mr. Dominick Colvin | CEO, Pres & Director | 1968 |
| Mr. John Hamilton Cassels C.A., CPA | CFO & Sec. | 1948 |
| Mr. Andrew Clifford Steedman | Chief Operations Officer | 1961 |
| Mr. Constantine Nkafu | Interim CEO & Director | 1976 |
| Mr. Oliver W. Foeste C.A., CPA | Chief Financial Officer | 1977 |
| Mr. Constantine Nkafu | CEO & Director | 1976 |
| Mr. Oliver W. Foeste C.A., CPA | Chief Financial Officer | 1976 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.